Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery

Summary

It has been suggested that preoperative fibrinogen plasma concentration is independently associated to postoperative blood loss after cardiac surgery.Theoretically, prophylactic infusion of fibrinogen concentrate may thus reduce postoperative bleeding, but this has not previously been investigated. Twenty elective coronary artery bypass graft (CABG) patients with preoperative plasma fibrinogen levels <3.8 g/l were included in a prospective randomised pilot study. Patients were randomised to receive an infusion of 2 g fibrinogen concentrate (FIB group) or no infusion before surgery (control group). Primary endpoint was safety with clinical adverse events and graft occlusion assessed by multi-slice computed tomography. Predefined secondary endpoints were postoperative blood loss, blood transfusions, haemoglobin levels 24 hours (h) after surgery, and global haemostasis assessed with thromboelastometry, 2 and 24 hours after surgery. Infusion of 2 g fibrinogen concentrate increased plasma levels of fibrinogen by 0.6 ± 0.2 g/l.There were no clinically detectable adverse events of fibrinogen infusion.Computed tomography revealed one subclinical vein graft occlusion in the FIB group. Fibrinogen concentrate infusion reduced postoperative blood loss by 32% (565 ± 150 vs. 830 ± 268 ml/12 h, p=0.010). Haemoglobin concentration was significantly higher 24 h after surgery in the FIB group (110 ± 12 vs. 98 ± 8 g/l, p=0.018). Prophylactic fibrinogen concentrate infusion did not influence global postoperative haemostasis as assessed by thromboelastometry. In conclusion, in this pilot study preoperative fibrinogen concentrate infusion reduced bleeding after CABG without evidence of postoperative hypercoagulability. Larger studies are necessary to ensure safety and confirm efficacy of prophylactic fibrinogen treatment in cardiac surgery.

Keywords

Fibrinogen - bleeding - cardiac surgery

• References

• 1 Moulton MJ, Creswell LL, Mackey ME. et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037-1046.
• 2 Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 08: 267-281.
• 3 Despotis GJ, Avidan MS, Hogue Jr CW. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001; 72: S1821-1831.
• 4 Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873-1881.
• 5 Scheraga HA. The thrombin-fibrinogen interaction. Biophys Chem 2004; 112: 117-130.
• 6 Aljassim O, Karlsson M, Wiklund L. et al. Inflammatory response and platelet activation after off-pump coronary artery bypass surgery. Scand Cardiovasc J 2006; 40: 43-48.
• 7 Blome M, Isgro F, Kiessling AH. et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 09: 1101-1107.
• 8 Karlsson M, Ternstrom L, Hyllner M. et al. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008; 48: 2152-2158.
• 9 Liu G, McNicol PL, McCall PR. et al. Prediction of the mediastinal drainage after coronary artery bypass surgery. Anaesth Intensive Care 2000; 28: 420-426.
• 10 Wahba A, Rothe G, Lodes H. et al. Predictors of blood loss after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1997; 11: 824-827.
• 11 Kreuz W, Meili E, Peter-Salonen K. et al. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci 2005; 32: 247-253.
• 12 Reininger AJ, Reininger CB, Spannagl M. et al. Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Thromb Haemost 1995; 74: 853-858.
• 13 Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J 2003; 24: 881-882.
• 14 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-246.
• 15 Westerberg M, Gabel J, Bengtsson A. et al. Hemodynamic effects of cardiotomy suction blood. J Thorac Cardiovasc Surg 2006; 131: 1352-1357.
• 16 Hillarp A, Egberg N, Nordin G. et al. Local INR calibration of the Owren type prothrombin assay greatly improves the intraand interlaboratory variation A three-year follow-up from the Swedish national external quality assessment scheme. Thromb Haemost 2004; 91: 300-307.
• 17 Lang T, Bauters A, Braun SL. et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16: 301-310.
• 18 Stainsby D, MacLennan S, Thomas D. et al. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135: 634-641.
• 19 Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99: 851-862.
• 20 Goldhaber SZ, Schoepf UJ. Pulmonary embolism after coronary artery bypass grafting. Circulation 2004; 109: 2712-2715.
• 21 Shammas NW. Pulmonary embolus after coronary artery bypass surgery: a review of the literature. Clin Cardiol 2000; 23: 637-644.
• 22 Lahtinen J, Ahvenjarvi L, Biancari F. et al. Pulmonary embolism after off-pump coronary artery bypass surgery as detected by computed tomography. Am J Surg 2006; 192: 396-398.
• 23 Poston RS, Gu J, Brown JM. et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006; 131: 122-130.
• 24 Fries D, Innerhofer P, Reif C. et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesthesia Analg 2006; 102: 347-351.
• 25 Velik-Salchner C, Haas T, Innerhofer P. et al. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2007; 05: 1019-1025.
• 26 Duchesne JC, Mathew KA, Marr AB. et al. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly. Am Surg 2008; 74: 1159-1165.